Prevalencia de genotipos del virus del papiloma humano de alto riesgo no vacunables dentro del programa de Detección Precoz de Cáncer de Cérvix en Cantabria

Abstract

According to the high percentage of non-vaccinable high oncogenic risk HPV types, there should be a re-think of the prevention strategy in the population, who may have a false sense of protection.

Knowledge, Attitudes, and Intentions towards Human Papillomavirus Vaccination among Nursing Students in Spain

“…Because of this limitation, we cannot generalize our results to nursing students with other characteristics (e.g., students who are socioeconomically advantaged) a priori. Fourth, bearing in mind the prevalence of high-risk HPV serotypes in Spanish women [32,33] and considering that not all of them are included in the currently available vaccine programs, it would have been interesting to determine the knowledge of nursing students about the level of protection offered by these vaccines; thus, there is a misunderstanding that the HPV vaccination is an alternative to cervical screening programs rather than a complementary strategy for cancer prevention [34,35]. Likewise, the false sense of protection of these vaccines could lead to a higher prevalence of risky lifestyles or sexual habits, such as a lower use of condoms [33,35], which is of great significance, especially for younger women [32].…”

Correlación entre el nivel de conocimiento y la actitud frente a la vacuna contra el virus del papiloma humano en estudiantes de secundaria

“…Correlación entre el nivel de conocimiento y la actitud frente a la vacuna contra el virus del papiloma humano en estudiantes de secundaria entre los 9 y 13 años sería lo más rentable para la economía del país, puesto que es una estrategia costo efectiva (17) . Se ha demostrado que la administración de vacunas tiene mayor eficacia a esa edad, sobre todo en las niñas, lo cual produce un impacto positivo en la protección comunitaria (18) , ya que brinda defensa sobre los genotipos de alto riesgo como son el 16 y 18 (19) . Se sugiere que el intervalo de vacunación entre ambas dosis sea de 6 meses (20) .…”